For patients with suspected Leptomeningeal Metastases, time matters – prompt diagnosis and treatment initiation are essential to improve the chances of controlling the disease, managing symptoms, and extending survival.
ACHIEVE CLARITY.
ACT WITH CERTAINTY.
CNSide® (Pronounced: see-inside)
CNSide®, a proprietary, highly sensitive, cerebrospinal fluid (CSF) assay platform performed in a CLIA accredited laboratory, provides healthcare professionals with accurate, comprehensive data that enable detection, quantitative analysis, and molecular characterization of tumor cells.1 The resulting data are indispensable in diagnosing LM, identifying biomarkers, and monitoring the effects of treatment.2
Leptomeningeal Metastases (LM)
Get information about this devastating complication of advanced cancer.
CNSide® Cerebrospinal Fluid Assay Platform
Our Company, Lab, and Dedicated Team
What Physician Experts Say
“CNSide® is a more sensitive and definitive test for LM and has the potential to permit earlier diagnosis, manage our patients with more diagnostic precision, and hopefully improve therapeutic outcomes for our patients with LM.”
Priya Kumthekar, MD
Principal Investigator, FORESEE Clinical Trial
Professor of Neurology and Medicine, Northwestern University
Full bio
Health Insurance Coverage
The some of the largest health insurance providers in the United States cover the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test for metastatic central nervous system cancer, including:
- United Healthcare
- Humana
- Highmark
